Invitrogen™ ELISA Kit for Human LYVE1

Ref.: BL-RE-092954Manufacturer ref.: EHLYVE1X10 10 x 96 tests
Price on request
Custom pricing depending on configuration and quantity.

LYVE1 was identified as a major receptor for HA (hyaluronane, extracellular matrix glycosaminoglycan) on the lymphatic vessel wall. The deduced amino acid sequence of LYVE1 predicts an integral membrane polypeptide...

Accession number
Q9Y5Y7
Dose range
8.19 to 2.000 pg/ml
Sensitivity of the dosage
8 pg/ml
Conjugate
Biotin
Product type
ELISA
Brand
Invitrogen

LYVE1 was identified as a major receptor for HA (hyaluronane, extracellular matrix glycosaminoglycan) on the lymphatic vessel wall. The deduced amino acid sequence of LYVE1 predicts an integral membrane polypeptide...

LYVE1 was identified as a major receptor for HA (hyaluronane, extracellular matrix glycosaminoglycan) on the lymphatic vessel wall. The amino acid sequence derived from LYVE1 predicted a 322-type full membrane polypeptide type I residues similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module, the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE1 molecule binds soluble HAs and immobilized HAs. However, unlike CD44, the LYVE1 molecule colocates with HA on the luminal side of the lymphatic vessel wall and is completely absent from the blood vessels. Therefore, LYVE1 is the first lymph specific HA receptor to be characterized and is a unique and powerful marker for the lymphatic vessels themselves. LYVE1 is a Type I integral membrane glycoprotein. LYVE-1 is primarily expressed on the endothelium of the lymphatic vessels and is likely to be involved in regulating the trafficking of leukocytes and tumour cells to the lymph nodes. Lymphatic vasculature forms a second circulatory system that drains extracellular fluid from tissues and provides an exclusive environment in which immune cells can meet and respond to foreign antigens. Several molecules were identified as markers for lymphatic lheendothelium that include LYVE1, PALE, VEGFR3 and podoplanin. Among the diseases associated with LYVE1 dysfunction, there is complete androgen insensitivity syndrome.

Sensitivity

Sensitivity of dosage: 8 pg/ml.

Measurement range

Dose range: 8.19 to 2.000 pg/ml.

Duration of dosing

Total duration of dosing: 4 h 45 min.

Reproducibility

Coefficient of intradose variation < 10%, interdose < 12%.

Target

Target: LYVE1.

Technical specifications

General
BrandInvitrogen
Supplier ref. (Fisher Scientific)17727973
Specifications
Accession numberQ9Y5Y7
Dose range8.19 to 2.000 pg/ml
Sensitivity of the dosage8 pg/ml
ConjugateBiotin
Product typeELISA
Type of samplePlasma, Serum, Surnatant
For use with (equipment)Colorimetric microplate reader
Genetic identification (Enter)10894
Gene symbol(s)Lyve1
Coefficient of inter-dose variation< 12%
Coefficient of intra-dose variation< 10%
Contents of kits96-well pre-coated plate, standard, dosing diluent concentrate, biotinylated detection antibody, SAV-HRP, washing pad, chromogen, stop solution, adhesive plate lids
Marker or dyeHRP
Quantity10 x 96 tests
Regulatory statusRUO
TargetLYVE1
Test time1 h 20 min
Physical characteristics
Volume of samplePlasma, 1 μl-Serum, 1 μl-Surnatant, 100 μl
Storage and shipping
Storage conditions2°C to 8°C
Total duration of dosing4 h 45 min

Origin and customs

Manufacturer ref.EHLYVE1X10
Country of originUnited States
HS customs code3002 12 00 00
A question or a specific configuration?
Contact us for a quote.